New England Journal of Medicine· 2014Q1

Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma

Héctor Ortega, Mark C. Liu, Ian Pavord, Guy Brusselle et al.

2,301citations
Q1SCImago
2014year

Short summary

Mepolizumab, a monoclonal antibody targeting IL-5, reduced asthma exacerbations by 47-53% and improved lung function (FEV1) and asthma control scores in patients with severe eosinophilic asthma compared to placebo over 32 weeks.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Physiology

PhysiologyMedicine